Mr. Lonnie Moulder Joins Trevena, Inc. Board of Directors

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc., a clinical-stage specialist GPCR company, today announced that Mr. Moulder has joined its Board of Directors.

Mr. Moulder is currently Chief Executive Officer of TESARO, Inc. an oncology-focused biopharmaceutical company he cofounded in May 2010. “Trevena is entering a crucial time in its corporate development,” explained Mr. Moulder about his decision. “They have superb science, great people, and exciting programs nearing clinical proof of concept. I’m thrilled to be involved.”

Trevena’s most advanced program, TRV027, is a biased AT1R ligand currently in Phase 2 studies for the treatment of acute heart failure. The company also has preclinical and discovery-stage programs targeting opioid receptors for pain. “We are delighted to welcome Mr. Moulder onto our Board,” said Maxine Gowen, Ph.D., President and Chief Executive Officer of Trevena, Inc. “His experience and track record will be invaluable during the next phase of Trevena’s development.”

Mr. Moulder brings a wealth of drug commercialization and corporate development experience to the Trevena board. He previously served as President and CEO of Abraxis BioScience (acquired by Celgene in 2010) and Executive Vice President of Eisai Corporation of North America following Eisai’s 2008 acquisition of MGI PHARMA, where he served as President and CEO since 2002. Prior to joining MGI PHARMA, he was Vice President, Business Development and Commercial Affairs, and a member of the founding management team of Eligix, Inc., which was a Boston based venture-stage biomedical company. This followed sixteen years of serving in various commercial positions with Hoechst Marion Roussel (now Sanofi-Aventis) and its predecessor companies, Marion Laboratories and Marion Merrell Dow Pharmaceuticals.

He began his career at Temple University Hospital as a clinical pharmacist. He currently serves as a director of Cubist Pharmaceuticals and a member of the board of visitors of the Temple University School of Pharmacy. Mr. Moulder received a bachelor’s degree in pharmacy from Temple University and a master’s degree in business administration from the University of Chicago.

About Trevena and “Biased Ligands”

Trevena, Inc. is the leader in the discovery and development of GPCR “biased ligand” drugs. By combining a powerful and efficient drug discovery platform with extensive development experience, Trevena has built a linked portfolio of novel biased medicines. The company's drug discovery technology is based on extensive research from the laboratories of leading scientists in the GPCR field - Robert J. Lefkowitz, M.D. and Howard A. Rockman, M.D. of Duke University Medical Center. Founded in 2008, Trevena is based in King of Prussia, Pennsylvania and is a privately held company backed by leading investors including Alta Partners, Healthcare Ventures, NEA, Polaris and Yasuda Enterprise Development Company. For more information about the company, please visit www.trevenainc.com.



CONTACT:

Trevena, Inc.
Arthur Fratamico
Chief Business Officer
610-354-8840
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Pharmaceutical  Other Science  Science

MEDIA:

Logo
 Logo

Suggested Articles

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.